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Abstract
Introduction Bcl-2 and Bcl-xL confer resistance to apoptosis,
thereby reducing the effectiveness of chemotherapy. We
examined the relationship between the expression of Bcl-2 and
Bcl-xL and chemosensitivity of breast cancer cells, with the aim
of developing specific targeted therapy.
Methods Four human breast cancer cell lines were examined,
and the effects of antisense (AS) Bcl-2  and AS Bcl-xL
phosphorothioate oligodeoxynucleotides (ODNs) on
chemosensitivity were tested in vitro and  in vivo.
Chemosensitivity was evaluated by the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide)
assay, and the antitumor effect was assessed in vivo by the
success of xenograft transplantation into athymic mice.
Results Treatment with AS Bcl-2 and Bcl-xL ODNs resulted in
a sequence-specific decrease in protein expression, compared
with controls. Treatment of BT-474, ZR-75-1, and MDA-MB-
231 cells with AS Bcl-2  increased chemosensitivity to
doxorubicin (DOX), mitomycin C (MMC), paclitaxel (TXL), and
docetaxel (TXT). Transfection of the Bcl-2 gene into MDA-MB-
453 cells decreased sensitivity to DOX and MMC. Treatment of
MDA-MB-231, BT-474, and ZR-75-1 cells with AS Bcl-xL
increased chemosensitivity to DOX, MMC and taxanes to a
smaller extent than AS Bcl-2. This occurred in the setting of
increased Bax and cleaved poly(ADP-ribose) polymerase, as
well as decreased Bcl-2 and pAkt. AS Bcl-2 ODNs induced
splenomegaly in association with increased serum IL-12, which
was attenuated by methylation of the CpG motifs of AS Bcl-2;
however, methylated CpG failed to negate the increased
antitumor effect of AS Bcl-2. Bcl-2 and Bcl-xL, to a smaller
extent, are major determinants of chemosensitivity in breast
cancer cells.
Conclusion Targeted therapy against Bcl-2 protein with the use
of AS ODNs might enhance the effects of chemotherapy in
patients with breast cancer.
Introduction
Bcl-2 and Bcl-xL proteins are inhibitors of the mitochondrial
apoptosis pathway; they exert their action by blocking their
proapoptotic counterparts, including Bid and Bax, thereby
preventing the release of cytochrome c and the activation of
caspase [1,2]. Bcl-xL shows remarkable homology to Bcl-2
and inhibits apoptosis as effectively as Bcl-2 in some cells.
Furthermore, Bcl-xL is capable of preventing cell death when
Bcl-2 fails to do so, suggesting that these proteins exert inde-
pendent effects on the mitochondrial apoptotic pathway [3].
Given that Bcl-2 and Bcl-xL are capable of inhibiting antican-
cer drug-induced apoptosis, which is mediated by the voltage-
dependent anion channel (VDAC) in the outer mitochondrial
membrane, overexpression of Bcl-2 and Bcl-xL might confer
resistance to chemotherapy [4]. In fact, overexpression of Bcl-
2 and Bcl-xL is observed in several cancers, including hema-
tologic malignancies, as well as a range of solid tumors, includ-
ing nasopharyngeal, colorectal, prostate, and breast cancer
[5-7].
Antisense oligodeoxynucleotides (AS ODNs) are short, syn-
thetic stretches of DNA that hybridize with specific mRNA
ANOVA = analysis of variance; AS = antisense; CREB = cyclic-AMP-responsive element-binding protein; DMSO = dimethyl sulfoxide; DOX = dox-
orubicin; ER = estrogen receptor; IL = interleukin; LSD = least significant difference; MM = mismatch control; MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-2H-tetrazolium bromide; ODN = oligodeoxynucleotide; PARP = poly(ADP-ribose) polymerase; RC = random control; TXL = paclitaxel; TXT 
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strands corresponding to target genes. By binding to mRNA,
AS ODNs prevent the translation of target proteins, thereby
blocking gene expression. Phosphorothioate ODNs, in which
the oxygen atom of the phosphodiester moiety of the DNA
backbone is replaced by sulphur, are the most commonly used
first-generation AS ODNs because they have acceptable
physical and chemical properties while showing resistance to
nucleases [8]. Several studies indicate that overexpression of
Bcl-2 inhibits apoptosis induced by anticancer drugs, radia-
tion, and other DNA-damaging agents [9,10]. In addition,
increased sensitivity to anticancer drugs after treatment with
AS Bcl-2 is observed in solid tumors, such as breast, prostate,
lung, and gastric cancer [11-14]. Similarly, downregulation of
Bcl-xL protein expression by AS ODNs in various tumor cell
lines resulted in activation of apoptosis, as well as decreased
cellular proliferation and increased sensitivity to cytotoxic
chemotherapeutic agents [15,16].
The two CpG motifs of AS Bcl-2, which are unmethylated
dinucleotide sequences of cytosine followed by guanine, are
associated with potent immune stimulation [17]. CpG ODNs
administered in the vicinity of various animal tumors show
marked antitumor activity [18,19]. However, it remains unclear
whether immune stimulation is responsible for the antitumor
effects of AS Bcl-2 ODNs.
In the present study we examined the effects of downregula-
tion of Bcl-2 and Bcl-xL on the chemosensitivity of breast can-
cer cells in vitro and in vivo with the aim of using this approach
as a specific targeting therapy. The possibility of using growth
inhibition as a mechanism by which AS Bcl-2 ODNs enhance
chemosensitivity was also explored. Furthermore, we studied
the effect of Bcl-2 gene transfection on the chemosensitivity
of a breast cancer cell line that normally expresses a low basal
level of Bcl-2. Finally, we attempted to evaluate the effects of
the two AS Bcl-2 CpG motifs on immunostimulatory function
and antitumor activity in athymic mice.
Materials and methods
Materials
The human breast cancer cell lines BT-474, ZR-75-1, MDA-
MB-231, and MDA-MB-453 were obtained from the American
Type Culture Collection (Manassas, VA, USA). Cells were cul-
tured in RPMI-1640 (Gibco BRL, New York, USA) containing
10% heat-inactivated fetal bovine serum and antibiotics. Cul-
tures were maintained in a humidified incubator at 5% CO2
and 37°C.
ODNs and anticancer drugs
Phosphorothioate ODNs, purified by reverse-phase high-per-
formance liquid chromatography, were purchased from Bio-
logica (Tokyo, Japan). The following AS Bcl-2 oligonucleotide
sequence, corresponding to the first six codons of the human
Bcl-2 open reading frame, was used: AS 5'-TCTC-
CCAGCGTGCGCCAT-3' [20]. The following Bcl-2 oligonu-
cleotide sequences were used as controls: 5'-
TCTCCCAGCATGTGCCAT-3' as a two-base mismatch con-
trol (MM), and 5'-TACCGCGTGCGACCCTCT-3' as a ran-
dom control (RC). Phosphorothioate oligonucleotides
corresponding to the initiation site of human Bcl-2 described
above were made with 5'-methylation of cytosine (m5C) resi-
dues in the two CpG motifs: 5'-
TCTCCCAGm5CGTGm5CGCCAT-3'. The following Bcl-xL
target sequence was used: 5'-CCATCCCGGAAGAGT-
TCATT-3'. In addition, the following Bcl-xL sequences were
used as a sense control and a two-base MM: 5'-AAT-
GAACTCTTCCGGGATGG-3' [16] and 5'-CCATCCCA-
GAAGAGTTTATT-3', respectively. The Bcl-2  and  Bcl-xL
sequences were not homologous with Bcl-xS  or with any
other known human gene sequences. All of the oligonucle-
otides were diluted to a concentration of 1 mM, filter-sterilized,
and stored at -30°C in distilled water. Doxorubicin (DOX) and
mitomycin C (MMC) were from Kyowa Hakko Co., Ltd (Tokyo,
Japan), paclitaxel (TXL) was from Bristol-Myers K.K. (Tokyo,
Japan), and docetaxel (TXT) was from Aventis Pharma (Tokyo,
Japan). DOX, MMC, and TXT were prepared with saline solu-
tion, and TXL was dissolved in dimethyl sulfoxide (DMSO).
Cell extraction and Western blotting
Cells were washed twice with PBS, centrifuged at 2,700 g
and 4°C, and lysed with lysis buffer containing 10 mM Tris-
HCl pH 8.0, 0.15 M NaCl, 1 mM EDTA, 10 mM CHAPS, 10
µg/ml aprotinin, and 0.02 mM phenylmethylsulfonyl fluoride.
Lysate was incubated for 15 min on ice and centrifuged for 15
min at 2,700 g. Supernatant was collected and the protein
quantity was estimated with Bio-Rad protein assay dye (Bio-
Rad, Hercules, CA, USA). Samples containing equal amounts
of protein (15 µg) were subjected to electrophoresis on a
12.5% sodium dodecyl sulfate-polyacrylamide gel, and trans-
ferred to a poly(vinylidene difluoride) membrane. After being
blocked overnight with PBS containing 5% nonfat milk pow-
der, the membrane was incubated with primary antibody
(1:200 dilution) for 1 hour at room temperature at 25°C. Anti-
bodies used for specific immune blotting included anti-Bcl-2,
anti-Bcl-xL, anti-Bax, anti-pAkt, anti-poly(ADP-ribose) polymer-
ase (anti-PARP), and anti-β-actin. All antibodies were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The
membrane was washed three times with PBS and then incu-
bated with anti-rabbit or anti-mouse IgG antibody (1:1,000
dilution; Sigma Chemical, St Louis, MO, USA) for 1 hour at
room temperature. After three washes with PBS, specific pro-
tein bands were detected with an enhanced chemilumines-
cence western blot detection system (ECL; Amersham
Pharmacia Biotech, Little Chalfont, Bucks, UK), and detected
after exposure to Hyper film ECL (Amersham Pharmacia Bio-
tech, Little Chalfont, Bucks, UK). Each protein signal was
quantified with Scion image software (Scion Corporation, Fre-
derick, MA, USA).Available online http://breast-cancer-research.com/content/7/6/R940
R942
MTT assays and cell viability
Cells were seeded into 96-well plates at 104 viable cells per
well and left to attach to the plate for 24 hours. After 24 hours,
cells were treated with anticancer drugs for 48 hours. The final
volume was 200 µl per well. Subsequently, 200 µl of medium
containing 0.25 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyl-2H-tetrazolium bromide (MTT; Sigma Chemical, Tokyo,
Japan) was added to each well for 3 hours. The medium was
then removed and 150 µl of DMSO (Wako Pure Chemical
Industries, Osaka, Japan) was added to each well for 30 min
at room temperature. The absorbance of each well was meas-
ured with a microculture plate reader at 540 nm. Growth inhi-
bition was expressed as a ratio of the mean absorbance of
drug-treated cells to that of control cells. Experiments were
performed in triplicate, and growth inhibition rates and IC50 val-
ues were calculated. Cell viability was also assessed with the
trypan blue dye-exclusion test.
Transfection
pZipneo plasmid expression vectors containing human bcl-2
cDNA were used [21]. MDA-MB-453 cells in the exponential
phase of growth were transfected with the pZipneo plasmid
expression vector with the use of Lipofectamine 2000 (Invitro-
gen Corp., Carlsbad, CA, USA), in accordance with the
instructions provided by the manufacturer. After this, cells
were selected with 400 µg/ml Geneticin Liquid (Gibco BRL,
New York, USA), and the resulting clones were pooled. The
Figure 1
Expression levels of Bcl-2 and Bcl-xL proteins in MDA-MB-231, MDA- MD-453, BT-474, and ZR-75-1 cells Expression levels of Bcl-2 and Bcl-xL proteins in MDA-MB-231, MDA-
MD-453, BT-474, and ZR-75-1 cells. (a) Western blot analysis of Bcl-2 
and Bcl-xL expression. (b) Quantification of Bcl-2 and Bcl-xL expres-
sion by densitometric analysis. The relative expression of Bcl-2 and Bcl-
xL in MDA-MB-453 cells was compared with the expression in MDA-
MB-231, BT-474, and ZR-75-1 cells. Results are from two representa-
tive, independent experiments.
Figure 2
Sequence-specific downregulation and cytotoxic effects of antisense  Bcl-2 oligodeoxynucleotides on BT-474 and ZR-75-1 cells Sequence-specific downregulation and cytotoxic effects of antisense 
Bcl-2 oligodeoxynucleotides on BT-474 and ZR-75-1 cells. (a) Spe-
cific inhibition of Bcl-2 protein expression by treatment with antisense 
(AS) Bcl-2 oligodeoxynucleotides (ODNs). Cells were treated with 10 
µg/ml Lipofectamine alone (control) or 1.0 µM AS, mismatch control 
(MM), or random control (RC) ODNs for 24 hours. Cells were then cul-
tured in standard medium, total protein was extracted, and Bcl-2 and β-
actin protein levels were analyzed by Western blotting. (b) Quantifica-
tion of Bcl-2 expression by densitometric analysis. The expression of 
Bcl-2 in cells treated with control, AS Bcl-2, RC Bcl-2, and MM Bcl-2 
ODNs was normalized with β-actin, and the relative values are pre-
sented. Error bars indicate SD. The data presented are from three inde-
pendent experiments. (c) Effects of AS Bcl-2 ODNs on the proliferation 
of BT-474 and ZR-75-1 breast cancer cells in vitro. Cells were treated 
with various concentrations of AS Bcl-2 ODNs in 24-well dishes. Four 
days after treatment, cells were stained with trypan blue and counted. 
Error bars indicate SD. The data presented are from three independent 
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expression of Bcl-2 by MDA-MB-453 cells was determined by
Western blotting with a monoclonal antibody against Bcl-2.
Antitumor activity in vivo
Four-week-old female athymic mice (Balb/c, nu/nu) were
obtained from Clea Japan (Tokyo, Japan). The research proto-
col was in accordance with the institutional guidelines of the
Hiroshima University Animal Care and Use Committee. BT-
474 (estrogen receptor (ER)-positive), ZR-75-1 (ER-positive),
and MDA-MB-231 (ER-negative), cells were established as
subcutaneous xenografts by the injection of 107 cells sus-
pended in 150 µl of Matrigel (Becton Dickinson Labware,
Bedford, MA, USA) in the lateral back region.
Mice were implanted subcutaneously with pellets engineered
to give a controlled release of 0.72 mg of 17β-estradiol over
60 days (Innovative Research, Sarasota, FL, USA) 1 week
before estrogen-dependent cell implantation. When palpable
tumors arose, three or four pieces (1 to 2 mm3) of nonnecrotic
tissue were subcutaneously transplanted into other mice with
the use of a biomedical stainless steel needle (implant needle)
under anesthesia. Once tumors had reached a volume of
about 100 mm3, mice were randomized to receive one of the
following treatments: no treatment (control group); treatment
with AS Bcl-2 or AS Bcl-xL ODNs; treatment with various anti-
cancer agents; or combined treatment with AS ODNs and var-
ious anticancer agents. AS Bcl-2 and AS Bcl-xL ODNs (5 mg/
kg) were administered by intraperitoneal injection 6 days a
week, every other week for 4 weeks. The anticancer agents
were administered once a week for 4 weeks as 10 mg/kg TXL
or TXT, or 2 mg/kg MMC, by intraperitoneal injection, or 6 mg/
kg doxorubicin by bolus injection into the tail vein. Serial meas-
urements of tumor diameter were made with calipers, and
tumor volumes were calculated as volume = width2 × length/2.
Serum levels of IL-12
Changes in serum levels of IL-12 after exposure to AS Bcl-2
ODNs, as well as AS Bcl-2  ODNs with methylated CpG
motifs (synthetic CpG AS Bcl-2 ODNs), were measured by
enzyme-linked immunosorbent assay (SRL, Tokyo, Japan); the
results were compared with control values. Changes in splenic
weight and serum IL-12 levels were evaluated after treatment
with AS Bcl-2 or synthetic CpG AS Bcl-2 ODNs.
Statistical analysis
All of the linear regression was performed with Microsoft Excel
(Seattle, WA, USA). Student's t-test was used to measure sta-
tistical significance between two treatment groups. Multiple
Table 1
Effect of antisense Bcl-2 oligodeoxynucleotides on chemosensitivity in BT-474, ZR-75-1, and MDA-MB-231 breast cancer cells
Cell line Drug IC50 (µM)a Fold increase in AS Bcl-2
Control Sense Bcl-2b AS Bcl-2b
BT-474 AS Bcl-2 3.6 -- -- --
DOX 1.0 0.97 0.12 8.3
MMC 1.4 1.3 0.81 1.7
TXL 2.4 2.3 0.29 8.3
TXT 0.54 0.50 0.054 10.0
ZR-75-1 AS Bcl-2 1.8 -- -- --
DOX 0.54 0.48 0.075 7.2
MMC 0.84 0.77 0.33 2.5
TXL 1.9 1.7 0.62 3.1
TXT 3.1 2.8 0.80 3.9
MDA-MB-231 AS Bcl-2 5.2 -- -- --
DOX 0.19 0.17 0.032 5.9
MMC 0.68 0.62 0.22 3.1
TXL 2.8 2.6 0.43 6.5
TXT 1.2 1.1 0.23 5.2
AS, antisense; DOX, doxorubicin; IC50, concentration for 50% inhibition; MMC, mitomycin C; TXL, paclitaxel; TXT, docetaxel.
aThe data are the means of three separate experiments (SD < 5%); bcells were treated with 1 µM sense Bcl-2 or antisense Bcl-2.Available online http://breast-cancer-research.com/content/7/6/R940
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comparisons were performed with a one-way analysis of vari-
ance (ANOVA). Data were considered significant if P < 0.05.
Results
Expression of Bcl-2 and Bcl-xL in breast cancer cell lines
To assess the expression of Bcl-2 and Bcl-xL in breast cancer
cell lines, western blot analysis was performed (Fig. 1). Bcl-2
and Bcl-xL proteins were expressed in MDA-MB-231, BT-474,
and ZR-75-1 cells, whereas Bcl-2 and Bcl-xL expression in
MDA-MB-453 cells was observed to a smaller extent. These
findings suggest differential regulation in the expression of
Bcl-2 and Bcl-xL protein in breast cancer cells.
Sequence-specific downregulation and cytotoxic effects 
of AS Bcl-2
We examined the effect of AS oligonucleotide treatment on
Bcl-2 protein expression. Western blot analysis showed that
BT-474 and ZR-75-1 cells transfected with 1.0 µM AS Bcl-2
oligonucleotides produced significantly less Bcl-2 protein than
cells treated with RC and MM oligonucleotides, or with Lipo-
fectamine alone. Bcl-2 protein expression was decreased by
70% and 50%, compared with control values, in BT-474 and
ZR-75-1 cells, respectively (Fig. 2a,b). Also, as shown in Fig.
2c, treatment of BT-474 and ZR-75-1 cells with AS Bcl-2 oli-
gonucleotides inhibited cell proliferation in a dose-dependent
manner. In contrast, control sense oligonucleotides had a min-
imal effect on cell growth at concentrations up to 1.0 µM.
Greater concentrations of control sense oligonucleotides had
cytotoxic effects. A dose–response effect with regard to
downregulation of Bcl-2 protein expression was observed in
ZR-75-1 and BT-474 cells, resulting in maximal inhibition
approaching 50% and 70%, respectively, at concentrations
up to 2.0 µM. However, the maximum inhibition of 70% for Bcl-
2 protein was also observed at 1.0 µM AS Bcl-2 ODNs, which
was the optimal dose for limiting cytotoxicity in the MDA-MB-
231 cell line (data not shown).
Effect of AS Bcl-2 on chemosensitivity
To evaluate whether treatment of BT-474, ZR-75-1, and MDA-
MB-231 cells with AS Bcl-2 in combination with anticancer
drugs enhances antitumor effects in vitro, we used the MTT
assay to examine the efficacy of DOX, MMC, TXL, and TXT in
the presence and absence of AS Bcl-2. BT-474, ZR-75-1, and
MDA-MB-231 cells were treated with 1.0 µM sense Bcl-2 or
AS Bcl-2, or Lipofectamine alone, for 24 hours, and then incu-
bated with various concentrations of anticancer drugs for a fur-
ther 48 hours. MTT assays were then performed to determine
cell viability. As shown in Table 1, although treatment with
sense Bcl-2 affected the chemosensitivity somewhat, treat-
ment of BT-474 cells with AS Bcl-2 resulted in 8.3-fold, 8.3-
fold, and 10.0-fold increases in sensitivity to DOX, TXL, and
TXT, respectively. In contrast, treatment with AS Bcl-2 and
MMC did not enhance the drug sensitivity of BT-474 cells to
the same extent. Treatment of ZR-75-1 cells with AS Bcl-2
resulted in 7.2-fold, 2.5-fold, 3.1-fold and 3.9-fold increases in
sensitivity to DOX, MMC, TXL, and TXT, respectively. Treat-
ment of MDA-MB-231 cells with AS Bcl-2 resulted in 5.9-fold,
3.1-fold, 6.5-fold and 5.2-fold increases in sensitivity to DOX,
MMC, TXL, and TXT, respectively. These results indicate that
downregulation of Bcl-2 by AS Bcl-2 ODNs in breast cancer
cells that normally overexpress Bcl-2 enhances their drug sen-
sitivity, especially the sensitivity to DOX and taxanes.
Sequence-specific downregulation and cytotoxic effects 
of AS Bcl-xL
We examined the effect of transfection with 1.0 µM AS Bcl-xL,
mismatch, and random ODNs, on Bcl-xL protein expression in
MDA-MB-231 and BT-474 cells (Fig. 3a). A 70% decrease in
Bcl-xL protein expression was observed in cells treated with
Figure 3
Sequence-specific downregulation and cytotoxic effects of antisense  Bcl-xL oligodeoxynucleotides on MDA-MB-231 and BT-474 cells Sequence-specific downregulation and cytotoxic effects of antisense 
Bcl-xL oligodeoxynucleotides on MDA-MB-231 and BT-474 cells. (a) 
Specific inhibition of Bcl-xL protein expression by treatment with anti-
sense (AS) Bcl-xL oligodeoxynucleotides (ODNs). Cells were treated 
with 10 µg/ml Lipofectamine alone (control) or 1.0 µM AS, mismatch 
control (MM), or random control (RC) ODNs for 24 hours. Cells were 
then cultured in standard medium, total protein was extracted, and Bcl-
xL and β-actin protein levels were analyzed by Western blotting. (b) 
Quantification of Bcl-xL protein expression by densitometric analysis. 
The Bcl-xL protein expression was normalized with β-actin, and the rela-
tive values are presented. Error bars indicate SD. The data presented 
are from three independent experiments. (c) Effects of AS Bcl-xL 
ODNs on the proliferation of MDA-MB-231 and BT-474 breast cancer 
cells in vitro. Cells were treated with various concentrations of AS Bcl-
xL ODNs in 24-well dishes. Four days after treatment, cells were 
stained with trypan blue and counted. Error bars indicate SD. The data 
presented are from three independent experiments.Breast Cancer Research    Vol 7 No 6    Emi et al.
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AS Bcl-xL ODNs, compared with control cells, but treatment
with mismatch or random ODNs produced little change. These
findings indicate that the effects of treatment with AS Bcl-xL
are due to its specificity for Bcl-xL mRNA. The decrease in
Bcl-xL protein expression by the treatment with AS Bcl-xL was
confirmed by quantification by densitometric analysis (Fig. 3b).
As shown in Fig. 3c, treatment with AS Bcl-xL ODNs resulted
in dose-dependent inhibition of cell proliferation. In contrast,
control sense oligonucleotides had minimal effects on cell
growth at concentrations up to 2.0 µM. Greater oligonucle-
otide concentrations resulted in cytotoxicity. The optimal dose
of AS Bcl-xL ODNs was determined as 1.0 µM to strike a bal-
ance between the dose–response effect and cytotoxicity. In
ZR-75-1 cells, the suppression of Bcl-xL protein expression by
AS Bcl-xL was also about 70%, and the optimal dose of AS
Bcl-xL was 1.0 µM, in terms of limiting its cytotoxicity (data not
shown).
Effect of AS Bcl-xL on chemosensitivity
We examined the chemosensitivity of MDA-MB-231, BT-474,
and ZR-75-1 cells to DOX, MMC, TXL, and TXT in the pres-
ence and absence of AS Bcl-xL with the MTT assay. As shown
in Table 2, although pretreatment with sense Bcl-xL affected
the chemosensitivity somewhat, the sensitivity to DOX, MMC,
TXL, and TXT in MDA-MB-231 cells was increased 2.5-fold,
3.6-fold, 2.9-fold, and 1.9-fold, respectively, by pretreatment
with AS Bcl-xL, as determined by increases in IC50 values. In
addition, drug sensitivity to DOX, MMC, TXL, and TXT in BT-
474 cells was increased 1.5-fold, 1.6-fold, 1.8-fold, and 2.1-
fold, respectively, and drug sensitivity to DOX, MMC, TXL, and
TXT in ZR-75-1 cells was increased 1.3-fold, 2.2-fold, 1.6-fold,
and 1.8-fold, respectively. These results indicate that down-
regulation of Bcl-xL by AS Bcl-xL enhances drug sensitivity,
but not to the same extent as downregulation of Bcl-2. This is
particularly true for DOX and taxanes.
Effect of transfection with the bcl-2 gene on 
chemosensitivity
To determine the effect of Bcl-2 on chemosensitivity, cell pro-
liferation was compared between MDA-MB-453/pZipneo and
MDA-MB-453/Bcl-2-1 cells, which were transfected with
empty plasmid vector or plasmid vector encoding the bcl-2
gene. As shown in Fig. 4, MDA-MB-453 cells were resistant to
DOX and MMC after transfection with the bcl-2 gene (P <
0.05, Student's t-test), whereas drug sensitivity to taxanes was
not changed. Two other clones transfected with the bcl-2
gene had similar drug sensitivities to those of control cells
transfected with vector alone (data not shown).
Table 2
Effect of antisense Bcl-xL oligodeoxynucleotides on chemosensitivity in BT-474, ZR-75-1, and MDA-MB-231 breast cancer cells
Cell line Drug IC50 (µM)a Fold increase in AS Bcl-xL
Control Sense Bcl-xLb AS Bcl-xLb
BT-474 AS Bcl-xL 4.0 -- -- --
DOX 1.0 0.92 0.68 1.5
MMC 1.4 1.32 0.88 1.6
TXL 2.4 2.2 1.34 1.8
TXT 0.54 0.51 0.26 2.1
ZR-75-1 AS Bcl-xL 1.8 -- -- --
DOX 0.54 0.51 0.71 1.3
MMC 0.84 0.79 0.39 2.2
TXL 1.9 1.8 1.2 1.6
TXT 3.1 3.0 1.7 1.8
MDA-MB-231 AS Bcl-xL 2.2 -- -- --
DOX 0.19 0.18 0.076 2.5
MMC 0.68 0.65 0.19 3.6
TXL 2.8 2.6 0.96 2.9
TXT 1.2 1.1 0.62 1.9
AS, antisense; DOX, doxorubicin; IC50, concentration for 50% inhibition; MMC, mitomycin C; TXL, paclitaxel; TXT, docetaxel.
aThe data are the means of three separate experiments (SD < 5%); bcells were treated with 1 µM sense Bcl-xL or antisense Bcl-xL.Available online http://breast-cancer-research.com/content/7/6/R940
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Effect of AS Bcl-2 on expression of apoptosis-related 
proteins
To investigate the effect of combined treatment with antican-
cer drugs and AS Bcl-2 on apoptosis, we analyzed the expres-
sion of apoptosis-related proteins by Western blotting. As
shown in Fig. 5, treatment with AS Bcl-2 and DOX markedly
suppressed Bcl-2 expression from that observed after treat-
ment with DOX alone. Combined treatment with AS Bcl-2 and
DOX enhanced the expression of Bax, which is a proapoptotic
protein, and inhibited phosphorylated Akt (pAkt), which is an
antiapoptotic protein. Furthermore, the cleaved PARP
increased over time after combined treatment with AS Bcl-2
and DOX, indicating an increased rate of apoptotic cell death.
Effect of combined treatment with AS Bcl-2 and various 
anticancer drugs in vivo
To investigate the effects of combined treatment with AS Bcl-
2 and various anticancer agents in vivo, we examined tumor
growth after combined treatment of BT-474 and ZR-75-1 cells
transplanted into athymic mice with AS Bcl-2 and MMC, DOX,
TXL, and TXT. On the basis of the protocols used in previous
ODN-treatment studies, mice were treated with 5 mg/kg AS
Bcl-2 and either 10 mg/kg TXL or TXT, 6 mg/kg DOX, or 2
mg/kg MMC [7,12,22]. As shown in Fig. 6a, Bcl-2 expression
was suppressed on day 4, and almost completely inhibited on
day 15, after treatment with AS Bcl-2, which was given by
intraperitoneal injection every other week for 4 weeks. In con-
trast, Bcl-xL did not change after treatment with AS Bcl-2.
Treatment of BT-474 cells with DOX, MMC, or TXT alone,
inhibited tumor growth, whereas treatment with TXL caused
less inhibition of tumor growth compared with control tumor
volumes. However, combined treatment with AS Bcl-2 and
various anticancer agents caused marked inhibition of tumor
growth (Fig. 6b). Statistical analysis showed significant
enhancement of the antitumor effect by combinations of AS
Bcl-2 and anticancer drugs in the treatment group (P < 0.05,
ANOVA with Fisher's least significant difference (LSD) test).
Similarly, combined treatment of ZR-75-1 cells with anticancer
drugs and AS Bcl-2 also enhanced the antitumor effects of
MMC, DOX, TXT, and TXL (Fig. 7). AS Bcl-2  statistically
enhanced sensitivities to all of the chemotherapeutic agents
(P < 0.05, ANOVA with Fisher's LSD test). None of the mice
treated with AS Bcl-2 and anticancer drugs displayed any
signs of toxicity. The toxicity of the combined treatments with
AS Bcl-2 and various anticancer drugs was assessed by com-
paring weight loss between treated and untreated mice. The
weight loss in treated mice was less than 10% (data not
shown).
Figure 4
Changes in chemosensitivity of MDA-MB-453 cells to anticancer drugs  after transfection with bcl-2 gene Changes in chemosensitivity of MDA-MB-453 cells to anticancer drugs 
after transfection with bcl-2 gene. (a) Expression levels of Bcl-2 and 
Bcl-xL were examined in MDA-MB-453 cells by Western blot analysis. 
MDA-MB-453 cells transfected with the bcl-2 gene expressed greater 
levels of Bcl-2 protein; however, similar levels of Bcl-xL protein were 
observed. (b) Cells treated with 0.15 µM doxorubicin (DOX) or with 2.0 
µM mitomycin C (MMC), paclitaxel (TXL) or docetaxel (TXT). After 48 
hours, cells were stained with trypan blue and counted. Each point rep-
resents the mean of triplicate experiments. Error bars indicate SD. *, P 
< 0.05, Student's t-test. The data presented are from three independ-
ent experiments.
Figure 5
Effect of treatment of ZR-75-1 cells with antisense Bcl-2 and doxoru- bicin on the apoptosis-related proteins Effect of treatment of ZR-75-1 cells with antisense Bcl-2 and doxoru-
bicin on the apoptosis-related proteins. Cells were pretreated with 10 
µg/ml Lipofectamine alone, or 1.0 µM antisense Bcl-2 oligodeoxynucle-
otides, for 24 hours. Cells were then cultured in standard medium, after 
which they were treated with 0.5 µM doxorubicin (DOX) for 6, 12, or 24 
hours. Whole cell lysate was then extracted and subjected to Western 
blotting. The data presented are from more than two independent 
experiments.Breast Cancer Research    Vol 7 No 6    Emi et al.
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Effects of combined treatment with AS Bcl-xL and 
various anticancer drugs in vivo
The effects of combined treatment with AS Bcl-xL and various
anticancer drugs were investigated with MDA-MB-231 cells
transplanted into athymic mice. As shown in Fig. 8a, Bcl-xL
expression was decreased on day 4, further decreased on day
6, and remained low 15 days after treatment with AS Bcl-xL.
In contrast, Bcl-2 did not change after AS Bcl-xL treatment.
Treatment with AS Bcl-xL alone inhibited tumor growth; how-
ever, AS Bcl-xL did not enhance the antitumor effects of anti-
cancer agents in MDA-MB-231 cells, apart from MMC (Fig.
8b). Statistical differences in tumor growth were not observed
in the combined and regular treatment groups, except for
MMC. Combined treatment with AS Bcl-xL  and MMC
significantly enhanced the antitumor effect of MMC (P < 0.05,
ANOVA with Fisher's LSD test). None of the mice treated with
AS Bcl-xL and anticancer drugs displayed any signs of toxic-
ity. The weight loss in treated mice was less than 10% (data
not shown).
Immunostimulatory and antitumor effects of AS Bcl-2 
compared with AS Bcl-2 with methylated CpG motifs
To evaluate the possible immunostimulatory role of the CpG
motifs of AS Bcl-2, we compared the effects of treatment with
AS Bcl-2  with treatment with synthetic CpG AS Bcl-2, in
which there is 5'-methylation of the CpG-motif cytosine resi-
dues. Mice were treated for 14 days by repeated daily bolus
injections of 5 mg/kg AS Bcl-2, synthetic CpG AS Bcl-2, or
saline control. Mice treated with AS Bcl-2  demonstrated
greater IL-12 levels and splenomegaly, compared with the
mice treated with saline and with synthetic CpG AS Bcl-2
(Fig. 9). Differences in IL-6 and IFN-γ levels were not observed
in mice treated with AS Bcl-2-treated and with synthetic CpG
AS Bcl-2 (data not shown). The antitumor effect of methylated
AS Bcl-2 was evaluated in BT-474 cells, and the results of
treatment with TXT and AS Bcl-2 were compared with those
of treatment with TXT and synthetic CpG AS Bcl-2. TXT was
given intraperitoneally once a week for 4 weeks, and AS Bcl-
2 was given intraperitoneally 6 days a week, every other week
Figure 6
Effects of treatment with antisense Bcl-2 and mitomycin C, doxorubicin, paclitaxel, or docetaxel on BT-474 cells Effects of treatment with antisense Bcl-2 and mitomycin C, doxorubicin, paclitaxel, or docetaxel on BT-474 cells. (a) Expression levels of Bcl-2 and 
Bcl-xL protein in BT-474 cells transplanted into athymic mice after treatment with antisense (AS) Bcl-2 oligodeoxynucleotides (ODNs) were meas-
ured by Western blot analysis at the indicated time points. (b) Enhancement of the antitumor effects of anticancer drugs by AS Bcl-2 ODNs in BT-
474 tumor xenografts. Each point represents the mean tumor volume of the eight mice in each group. Error bars indicate SD. *, P < 0.05, analysis of 
variance with Fisher's least significant difference test. The data presented are from two independent experiments. MMC, mitomycin C; DOX, doxoru-
bicin; TXL, paclitaxel; TXT, docetaxel.Available online http://breast-cancer-research.com/content/7/6/R940
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for 4 weeks. As shown in Fig. 10, treatment with TXT and AS
Bcl-2, as well as that with TXT and synthetic CpG AS Bcl-2,
resulted in enhanced sensitivity to TXT. In addition, no differ-
ences in the antitumor effects of AS Bcl-2 and synthetic CpG
AS Bcl-2 were observed.
Discussion
In the present study we showed that treatment with AS Bcl-2
and AS Bcl-xL ODNs produced sequence-specific decreases
in protein levels, thereby enhancing the chemosensitivity of
BT-474, ZR-75-1, and MDA-MB-231 breast cancer cells to
various anticancer drugs both in vitro and in vivo. Treatment
with AS Bcl-2 caused greater enhancement of chemosensitiv-
ity than treatment with AS Bcl-xL. A number of factors might
explain the different effects of AS Bcl-2 and AS Bcl-xL on
chemosensitivity, despite the fact that both Bcl-2 and Bcl-xL
inhibit apoptotic cell death through the mitochondrial pathway.
One determining factor might be the differential expression of
Bcl-2 and Bcl-xL in breast cancer cells. Overexpression of Bcl-
2 is observed more frequently than overexpression of Bcl-xL
(70% versus 40%) in breast cancer tissue, which suggests a
more important role for Bcl-2 in conferring drug resistance.
Another influencing factor might be a difference in the ability
of sequence-specific AS ODNs to suppress Bcl-2 and Bcl-xL
expression. Although our results indicate that greater suppres-
sion of Bcl-2 than Bcl-xL was achieved, the in vitro and in vivo
data obtained in this study suggest that differences in Bcl-2
and Bcl-xL suppression do not fully explain their differing
effects on chemosensitivity. The differential effects of Bcl-2
and Bcl-xL on drug sensitivity might be unique to breast can-
cer. In addition, despite similarities in function in the Bcl-2 fam-
ily proteins, there is evidence to suggest that Bcl-2 and Bcl-xL
are subject to different regulatory mechanisms. Bcl-2 inhibits
Bid-induced apoptosis at the mitochondrial level by blocking
cytochrome  c  release, whereas Bcl-xL does not affect the
insertion of tBid into mitochondrial membranes [23,24]. Some
reports suggest that Bcl-xL, but not Bcl-2, is capable of
modulating apoptosis induced by tumor necrosis factor-
related apoptosis ligand (TRAIL) [25].
With regard to the effects of AS Bcl-2 on chemosensitivity,
sensitivity to DOX and taxanes in vitro was increased to a
greater extent than sensitivity to MMC in BT-474, ZR-75-1,
and MDA-MB-231 cells. Moreover, enhanced sensitivity to
DOX and taxanes was more pronounced in BT-474 cells than
in ZR-75-1 cells. These findings suggest that the downregula-
tion of Bcl-2 expression by AS Bcl-2 enhances drug sensitivity
by modulating the apoptotic signal transduction pathway of
Bcl-2. The apoptotic signal transduction pathway commonly
induced by anticancer agents is associated with the induction
of Bax and cleaved PARP, and the downregulation of Bcl-2
and pAkt. Bcl-2 expression is regulated by the ER-responsive
element of the promoter region of the bcl-2 gene [26], such
Figure 7
Effects of treatment with antisense Bcl-2 and mitomycin C, doxorubicin, paclitaxel, or docetaxel on ZR-75-1 cells Effects of treatment with antisense Bcl-2 and mitomycin C, doxorubicin, paclitaxel, or docetaxel on ZR-75-1 cells. Enhancement of the antitumor 
effects of anticancer drugs by antisense Bcl-2 oligodeoxynucleotides in ZR-75-1 tumor xenografts. Each point represents the mean tumor volume of 
the eight mice in each group. Error bars indicate SD. *, P < 0.05, analysis of variance with Fisher's least significant difference test. The data pre-
sented are from two independent experiments. MMC, mitomycin C; DOX, doxorubicin; TXL, paclitaxel; TXT, docetaxel.Breast Cancer Research    Vol 7 No 6    Emi et al.
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that overexpression of Bcl-2 might be expected to confer
greater drug resistance on ER-positive breast cancer cells.
Increases in chemosensitivity to DOX and taxanes in vitro did
not correlate well with antitumor activity in vivo, suggesting
that other factors might influence the response of athymic
mice to chemotherapeutic agents. The converse was
observed for combined treatment of MDA-MB-231 cells with
AS  Bcl-xL  and MMC, for which far greater efficacy was
observed in vivo than in vitro.
The role of Bcl-2 in determining the chemosensitivity of breast
cancer cells was tested in MDA-MB-453 cells expressing low
levels of Bcl-2. Transfection of the bcl-2 gene into MDA-MB-
453 cells decreased their sensitivity to DOX and MMC but not
to taxanes such as TXL and TXT. Several studies indicate that
in vitro treatment with taxanes induces phosphorylation and
inactivation of the Bcl-2 protein as well as apoptosis [27],
which might explain why Bcl-2-transfected cells retained their
sensitivity to taxanes in the present experiment. Because the
enforced overexpression of Bcl-2 can act as an antioxidant in
response to DNA damage, the decreased chemosensitivity of
the Bcl-2-transfected breast cancer cells to DNA-damaging
agents, including DOX and MMC, may be explained by this
effect.
Akt is another antiapoptotic protein that belongs to the serine/
threonine kinase family. Bcl-2 is activated by Akt through a
cyclic-AMP-responsive element-binding protein (CREB) [28].
An Akt- and Bcl-2-dependent pathway might mediate the pre-
vention of anticancer drug-induced cell death through CREB
and NF-κB. Because downregulation of Bcl-2 by AS Bcl-2
might result in downregulation of pAkt, downregulation of pAkt
after treatment with DOX might be augmented by concurrent
treatment of ZR-75-1 cells with AS Bcl-2.
Previous reports have suggested that AS ODNs have immu-
nostimulatory effects due to their CpG motifs, in addition to
their AS activity [29]. In the present study we observed
immune stimulation by CpG motifs, resulting in significant
spleen enlargement and elevated serum IL-12 levels. How-
ever, the role of immune stimulation in mediating antitumor
activity remains uncertain because AS Bcl-2 ODNs with meth-
ylated CpG motifs, when transplanted into athymic mice,
demonstrated antitumor activities that were similar to those of
Figure 8
Effects of treatment with antisense Bcl-xL and mitomycin C, doxorubicin, paclitaxel, or docetaxel on MDA-MB-231 cells Effects of treatment with antisense Bcl-xL and mitomycin C, doxorubicin, paclitaxel, or docetaxel on MDA-MB-231 cells. (a) Expression levels of Bcl-
xL and Bcl-2 protein in MDA-MB-231 cells transplanted into athymic mice after treatment with antisense (AS) Bcl-xL oligodeoxynucleotides (ODNs) 
were measured by Western blot analysis at the indicated time points. (b) Enhancement of the antitumor effects of anticancer drugs by AS Bcl-xL 
ODNs in MDA-MB-231 tumor xenografts. Each point represents the mean tumor volume of the four mice in each group. Error bars indicate SD. *, P 
< 0.05, analysis of variance with Fisher's least significant difference test. The data presented are from two independent experiments. MMC, mitomy-
cin C; DOX, doxorubicin; TXL, paclitaxel; TXT, docetaxel.Available online http://breast-cancer-research.com/content/7/6/R940
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their nonmethylated counterparts with immunostimulatory
activity. We therefore suggest that the therapeutic activity of
AS Bcl-2 is due to the AS–mRNA interaction and not to immu-
nostimulatory effects in this model. Similarly, methylated AS
Bcl-2, with 5'-methylation of CpG motif cytosine residues, had
the same antitumor effect as unmethylated AS Bcl-2 ODNs in
human melanoma xenografts transplanted into mice with
severe combined immunodeficiency [30]. However, given that
AS Bcl-2 stimulates IL-12 secretion and results in the devel-
opment of splenomegaly, effects that are not observed with
methylated AS Bcl-2, Th1-mediated immunostimulation may
have antitumor effects in solid tumors in humans. Further stud-
ies are required to determine whether the immunostimulatory
effects of the CpG motifs in AS Bcl-2 have antitumor effects
in the clinical setting.
Phase III clinical trials using Genasense (known as G3139) in
the treatment of patients with chronic lymphocyctic leukemia,
malignant melanoma, and multiple myeloma are complete, and
are nearly complete for non-small cell lung cancer [31].
Although a phase III trial of G3139/dacarbazine versus dacar-
bazine alone in advanced malignant melanoma does not show
a significant increase in overall survival by the addition of
G3139, combination treatment with G3139 and dacarbazine
shows a significant increase in progression-free survival and
response rate, compared with dacarbazine alone [32]. The
results of other phase III trials are eagerly anticipated. In addi-
tion, phase I and II trials of G3139 in advanced esophageal,
Figure 9
Effect of antisense Bcl-2 oligodeoxynucleotides on splenomegaly development and serum IL-12 levels in athymic mice Effect of antisense Bcl-2 oligodeoxynucleotides on splenomegaly development and serum IL-12 levels in athymic mice. (a) Segment of spleen from 
a mouse with splenomegaly after treatment with antisense (AS) Bcl-2 oligodeoxynucleotides (ODNs), and segments from untreated (control) and 
synthetic CpG AS Bcl-2 ODN-treated mice. (b) Comparison of splenic weight among mice treated with AS Bcl-2 ODNs, synthetic CpG AS Bcl-2 
ODNs, and control mice. (c) Increased serum levels of IL-12 were observed in mice treated with AS Bcl-2 ODNs, compared with those treated with 
synthetic CpG AS Bcl-2 ODNs, and with control mice. Each point represents the mean of the three mice in each group. Error bars indicate SD. The 
data presented are from three independent experiments.
Figure 10
Effect of synthetic CpG antisense Bcl-2 on BT-474 cells in comparison  with antisense Bcl-2 Effect of synthetic CpG antisense Bcl-2 on BT-474 cells in comparison 
with antisense Bcl-2. Each point represents the mean tumor volume of 
the four mice in each group. Error bars indicate SD. The data presented 
are from two independent experiments. RC, random control; TXT, 
docetaxel.Breast Cancer Research    Vol 7 No 6    Emi et al.
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gastric, and colon cancer are ongoing, as are trials in hepato-
cellular carcinoma, metastatic breast cancer, and hormone
refractory prostate cancer.
Conclusion
Although AS therapy targeting Bcl-2 and Bcl-xL enhances
chemosensitivity in breast cancer cells, the effect of blocking
Bcl-2 seems superior to that of Bcl-xL. Downregulation of Bcl-
2 is associated with enhancement of chemosensitivity to
agents such as DOX and taxanes. AS Bcl-2-mediated
downregulation of Bcl-2 augments anticancer drug-induced
signal transduction pathways leading to apoptosis, which is
associated with the activation of proapoptotic proteins such
as Bax and the suppression of antiapoptotic proteins such as
Bcl-2 and pAkt. Although AS Bcl-2 ODNs induced splenome-
galy and increased serum IL-12 levels in the present experi-
ment, suggesting an immunostimulatory effect of AS Bcl-2,
the antitumor effect of AS Bcl-2 ODNs seemed to result from
downregulation of Bcl-2, independently of CpG-mediated
immune stimulation.
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